small fontsmall fontsmall fontChange Font Size
Print this pagePrint
Create PDFCreate PDF

Welcome to


The European Commission has granted Pfizer Inc a European marketing authorization for its pneumococcal conjugate vaccine, Prevenar 13* (Pneumococcal Polysaccharide Conjugate Vaccine [13-valent, adsorbed]).


Prevenar 13 is indicated for active immunization for the prevention of invasive disease, pneumonia, and acute otitis media caused by 13 Streptococcus pneumoniae serotypes in infants and children from 6 weeks to 5 years of age.


Read the full press release



If you are a journalist please click here to register to


If you are a US health care professional please visit our website for more information.



*Prevenar 13 is a registered trade mark of Pfizer